EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S1	2	"6429311".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/05 12:38
S2	20	("5798344"|"6331541"|"6444686"|"6492400"|"6521592"|"6525069"|"6605623"|"6780857"|"6875776"|"6897234"|"6906066"|"6919368").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/05/31 12:15
S3	783	quinazolinone.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/04 16:07
S4	344	hansch.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/04 13:40
S5	0	hansch.in. and qsar	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/04 13:40
S6	0	hansch.in. and structure adj activity	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/04 13:41
S7	0	hansch.in. and pharma$	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/04 13:41

EAST Search History

S8	0	hansch-$.in. and pharma$	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/04 13:42
S9	342	hansch-$.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/04 13:42
S10	0	hansch-$.in. and drug	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/04 13:42
S11	2	dihydro adj quinazolinone.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/04 16:07
S12	6	quinazolinone.ab. and prostaglandin	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/04 16:16
S13	165	quinazolinone and prostaglandin	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/04 16:16
S14	159	quinazolinone and prostaglandin not S12	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/04 16:25

EAST Search History

S15	2	"6759410".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/04 16:25
S16	5	"3375250".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/06/05 12:29
S17	3	"3843654".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/06/05 12:29
S18	3	"3843654".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/06/05 16:17

Author Search

```
=> FILE CAPLUS
FILE 'CAPLUS' ENTERED AT 10:29:16 ON 25 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 25 May 2007  VOL 146 ISS 23
FILE LAST UPDATED: 24 May 2007  (20070524/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> D QUE L11
L3              STR


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation:
Uploading strA.str
```




```
chain nodes :
11  12  15  16  17  23  24  25  26  27  28  29  30  31  32  33  34  35  42  43  44
58  59  66  67
ring nodes :
1  2  3  4  5  6  7  8  9  10  18  19  20  21  22  36  37  38  39  40  41  45  46
47  48  49  50  51  52  53  54  55  56  57
chain bonds :
7-11  8-66  9-15  16-17  17-18  23-24  24-25  25-26  25-27  28-29  29-30  30-31
31-32  31-33  34-35  35-36  39-42  42-43  42-44  45-58  51-67  58-59
ring bonds :
1-2  1-6  2-3  3-4  4-5  4-7  5-6  5-10  7-8  8-9  9-10  18-19  18-22  19-20  20-21
21-22  36-37  36-41  37-38  38-39  39-40  40-41  45-46  45-50  46-47  47-48  48-49
48-51  49-50
49-53  51-52  52-53  52-54  53-57  54-55  55-56  56-57
exact/norm bonds :
4-7  5-10  7-8  7-11  8-9  8-66  9-10  9-15  16-17  18-19  18-22  19-20  20-21  21-
22
23-24  28-29  34-35  39-42  48-51  49-53  51-52  51-67  58-59
exact bonds :
17-18  24-25  25-26  25-27  29-30  30-31  31-32  31-33  35-36  42-43  42-44  45-58

normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  36-37  36-41  37-38  38-39  39-40  40-41  45-46  45-
50
46-47  47-48  48-49  49-50  52-53  52-54  53-57  54-55  55-56  56-57


G1:Ak,[*1]

G2:[*2],[*3],[*4],[*5],[*6]

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:CLASS  12:Atom  15:CLASS  16:CLASS  17:CLASS  18:Atom  19:Atom  20:Atom  21:Atom
22:Atom  23:CLASS
24:CLASS  25:CLASS  26:CLASS  27:CLASS  28:CLASS  29:CLASS  30:CLASS  31:CLASS
32:CLASS  33:CLASS
34:CLASS  35:CLASS  36:Atom  37:Atom  38:Atom  39:Atom  40:Atom  41:Atom  42:CLASS
43:CLASS
44:CLASS  45:Atom  46:Atom  47:Atom  48:Atom  49:Atom  50:Atom  51:Atom  52:Atom
53:Atom  54:Atom
55:Atom  56:Atom  57:Atom  58:CLASS  59:CLASS  66:CLASS  67:CLASS
Generic attributes :
12:
Saturation              : Unsaturated
67:
Number of Carbon Atoms : less than 7



L5            86 SEA FILE=REGISTRY SSS FUL L3
L6             4 SEA FILE=CAPLUS ABB=ON  PLU=ON  L5
L7           266 SEA FILE=CAPLUS ABB=ON  PLU=ON  ITAI A?/AU
L8          1390 SEA FILE=CAPLUS ABB=ON  PLU=ON  MUTO S?/AU
L9         11982 SEA FILE=CAPLUS ABB=ON  PLU=ON  INOUE T?/AU
L10          262 SEA FILE=CAPLUS ABB=ON  PLU=ON  URADE Y?/AU
L11            1 SEA FILE=CAPLUS ABB=ON  PLU=ON  (L7 OR L8 OR L9 OR L10) AND L6
```



```
=> D IBIB ED ABS HITSTR L11 1

L11  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2004:308434  CAPLUS  Full-text
DOCUMENT NUMBER:          140:339338
TITLE:                    Preparation of quinazolin-4-one derivatives as PGD2
                          synthetase inhibitors
INVENTOR(S):              Itai, Akiko; Muto, Susumu;
                          Inoue, Tsuyoshi; Urade, Yoshihiro
PATENT ASSIGNEE(S):       Institute of Medicinal Molecular Design. Inc., Japan
SOURCE:                   PCT Int. Appl., 96 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 Japanese
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ----------------    ----   --------    --------------------   --------
     WO 2004031180        A1    20040415    WO 2003-JP12648        20031002
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
             GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
             PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
             TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2503674           A1    20040415    CA 2003-2503674        20031002
     AU 2003268735        A1    20040423    AU 2003-268735         20031002
     GB 2410025           A     20050720    GB 2005-7682           20031002
     GB 2410025           B     20070328
     US 2006229324        A1    20061012    US 2005-529946         20051004
PRIORITY APPLN. INFO.:                       JP 2002-291114      A  20021003
                                             WO 2003-JP12648     W  20031002

OTHER SOURCE(S):          MARPAT 140:339338
ED   Entered STN:  15 Apr 2004
GI
```



I



II

AB The title compds. I [wherein X = (un)substituted N=CH or NHCH2; R1-R4 = independently H, halo, (un)substituted alkyl, or OH; R = (un)substituted NH2] or pharmaceutically acceptable salts, hydrates, or solvates thereof are

prepared as prostaglandin D2 synthase (PGD2) inhibitors. For example, the compound II was prepared in a four-step synthesis. Compds. I showed strong inhibitory effect against human PGD2.

IT 679843-64-2P
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(drug candidate; preparation of quinazolinone derivs. as PGD2 synthetase inhibitors)

RN 679843-64-2 CAPLUS

CN 4(1H)-Quinazolinone, 2,3-dihydro-2-(hydroxymethyl)-3-[[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]- (9CI) (CA INDEX NAME)



IT 679843-65-3P 679843-66-4P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of quinazolinone derivs. as PGD2 synthetase inhibitors)

RN 679843-65-3 CAPLUS

CN 4(1H)-Quinazolinone, 2,3-dihydro-2-(hydroxymethyl)-3-[[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 679843-66-4 CAPLUS

CN 4(1H)-Quinazolinone, 2,3-dihydro-2-(hydroxymethyl)-3-[[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



IT 679843-30-2P 679843-34-6P 679843-35-7P
679843-37-9P 679843-38-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of quinazolinone derivs. as PGD2 synthetase inhibitors)
RN 679843-30-2 CAPLUS
CN Acetic acid, [[3-methyl-4-[[(2-methyl-4-oxo-3(4H)-quinazolinyl)imino]methyl]-1-phenyl-1H-pyrazol-5-yl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 679843-34-6 CAPLUS
CN 1H-Pyrazole-3-propanoic acid, 5-hydroxy-4-[[(2-methyl-4-oxo-3(4H)-quinazolinyl)imino]methyl]-1-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 679843-35-7 CAPLUS
CN 1H-Pyrazole-3-propanoic acid, 5-hydroxy-4-[[(2-methyl-4-oxo-3(4H)-quinazolinyl)imino]methyl]-1-phenyl- (9CI) (CA INDEX NAME)



RN 679843-37-9 CAPLUS
CN 1H-Pyrazole-3-butanoic acid, 5-hydroxy-4-[[(2-methyl-4-oxo-3(4H)-quinazolinyl)imino]methyl]-1-phenyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 679843-38-0 CAPLUS
CN 1H-Pyrazole-3-butanoic acid, 5-hydroxy-4-[[(2-methyl-4-oxo-3(4H)-quinazolinyl)imino]methyl]-1-phenyl- (9CI) (CA INDEX NAME)



IT 371120-60-4P 384353-13-3P 384812-90-2P
679843-29-9P 679843-31-3P 679843-32-4P
679843-33-5P 679843-36-8P 679843-39-1P
679843-40-4P 679843-41-5P 679843-42-6P
679843-43-7P 679843-44-8P 679843-45-9P
679843-46-0P 679843-47-1P 679843-48-2P
679843-49-3P 679843-50-6P 679843-51-7P
679843-52-8P 679843-53-9P 679843-54-0P
679843-55-1P 679843-56-2P 679843-57-3P
679843-58-4P 679843-59-5P 679843-60-8P
679843-61-9P 679843-62-0P 679843-63-1P
679843-67-5P 679843-68-6P 679843-69-7P
679843-70-0P 679843-71-1P 679843-72-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of quinazolinone derivs. as PGD2 synthetase inhibitors)
RN 371120-60-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[[5-hydroxy-3-methyl-1-(4-methylphenyl)-1H-pyrazol-4-yl]methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 384353-13-3 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 384812-90-2 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 679843-29-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[(5-ethoxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 679843-31-3 CAPLUS
CN Acetic acid, [[3-methyl-4-[[(2-methyl-4-oxo-3(4H)-quinazolinyl)imino]methyl]-1-phenyl-1H-pyrazol-5-yl]oxy]- (9CI) (CA INDEX

NAME)



RN 679843-32-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[[3-ethyl-5-hydroxy-1-phenyl-1H-pyrazol-4-yl]methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 679843-33-5 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[[5-hydroxy-1-phenyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 679843-36-8 CAPLUS
CN 1H-Pyrazole-3-propanamide, 5-hydroxy-4-[[(2-methyl-4-oxo-3(4H)-quinazolinyl)imino]methyl]-1-phenyl- (9CI) (CA INDEX NAME)



RN 679843-39-1 CAPLUS
CN 1H-Pyrazole-3-butanamide, 5-hydroxy-4-[[(2-methyl-4-oxo-3(4H)-quinazolinyl)imino]methyl]-1-phenyl- (9CI) (CA INDEX NAME)



RN 679843-40-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[(5-hydroxy-1,3-dimethyl-1H-pyrazol-4-yl)methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 679843-41-5 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[[1-(2-chlorophenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 679843-42-6 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[[1-(3-chlorophenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 679843-43-7 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[[1-(4-chlorophenyl)-5-hydroxy-3-methyl-1H-pyrazol-4-yl]methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 679843-44-8 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[[5-hydroxy-1-(4-methoxyphenyl)-3-methyl-1H-pyrazol-4-yl]methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 679843-45-9 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[[5-hydroxy-3-methyl-1-(4-nitrophenyl)-1H-pyrazol-4-yl]methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 679843-46-0 CAPLUS
CN 4(3H)-Quinazolinone, 2-ethyl-3-[[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]- (9CI) (CA INDEX NAME)



RN 679843-47-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-

yl)methylene]amino]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 679843-48-2 CAPLUS
CN 4(3H)-Quinazolinone, 2-butyl-3-[[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]- (9CI) (CA INDEX NAME)



RN 679843-49-3 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-2-phenyl- (9CI) (CA INDEX NAME)



RN 679843-50-6 CAPLUS
CN 4(3H)-Quinazolinone, 2-(1,1-dimethylethyl)-3-[[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]- (9CI) (CA INDEX NAME)



RN 679843-51-7 CAPLUS
CN 4(3H)-Quinazolinone, 2-(hydroxymethyl)-3-[[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]- (9CI) (CA INDEX NAME)



RN 679843-52-8 CAPLUS
CN Acetic acid, [[4-[[[2-(hydroxymethyl)-4-oxo-3(4H)-quinazolinyl]imino]methyl]-3-methyl-1-phenyl-1H-pyrazol-5-yl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 679843-53-9 CAPLUS
CN 4(3H)-Quinazolinone, 2-(hydroxymethyl)-3-[[[5-hydroxy-1-phenyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]methylene]amino]- (9CI) (CA INDEX NAME)



RN 679843-54-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-2-(methoxymethyl)- (9CI) (CA INDEX NAME)



RN 679843-55-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 679843-56-2 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-2-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 679843-57-3 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-2-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 679843-58-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 679843-59-5 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-2,8-dimethyl- (9CI) (CA INDEX NAME)



RN 679843-60-8 CAPLUS
CN 4(3H)-Quinazolinone, 6-chloro-3-[[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 679843-61-9 CAPLUS
CN 4(3H)-Quinazolinone, 7-chloro-3-[[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 679843-62-0 CAPLUS
CN 4(3H)-Quinazolinone, 6-bromo-3-[[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 679843-63-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[(5-hydroxy-3-methyl-1-phenyl-1H-pyrazol-4-yl)methylene]amino]-6,7-dimethoxy-2-methyl- (9CI) (CA INDEX NAME)



RN 679843-67-5 CAPLUS
CN 4(3H)-Quinazolinone, 3-[(2,2-diphenylethylidene)amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 679843-68-6 CAPLUS
CN 4(3H)-Quinazolinone, 3-[(3,3-diphenyl-2-propenylidene)amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 679843-69-7 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[[3-[4-(1,1-dimethylethyl)phenyl]-5-hydroxy-1-phenyl-1H-pyrazol-4-yl]methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 679843-70-0 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[(5-hydroxy-1-phenyl-3-tricyclo[3.3.1.13,7]dec-1-yl-1H-pyrazol-4-yl)methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 679843-71-1 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[[4-(diphenylamino)phenyl]methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 679843-72-2 CAPLUS
CN 4(3H)-Quinazolinone, 3-[[(9-ethyl-9H-carbazol-3-yl)methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


```
=>
=> D QUE L6
L3              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation:
Uploading strA.str
```



```
chain nodes :
11 12 15 16 17 23 24 25 26 27 28 29 30 31 32 33 34 35 42 43 44
58 59 66 67
ring nodes :
1 2 3 4 5 6 7 8 9 10 18 19 20 21 22 36 37 38 39 40 41 45 46
47 48 49 50 51 52 53 54 55 56 57
chain bonds :
7-11 8-66 9-15 16-17 17-18 23-24 24-25 25-26 25-27 28-29 29-30 30-31
31-32 31-33 34-35 35-36 39-42 42-43 42-44 45-58 51-67 58-59
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 8-9 9-10 18-19 18-22 19-20 20-21
21-22 36-37 36-41 37-38 38-39 39-40 40-41 45-46 45-50 46-47 47-48 48-49
48-51 49-50
49-53 51-52 52-53 52-54 53-57 54-55 55-56 56-57
exact/norm bonds :
4-7 5-10 7-8 7-11 8-9 8-66 9-10 9-15 16-17 18-19 18-22 19-20 20-21 21-
22
23-24 28-29 34-35 39-42 48-51 49-53 51-52 51-67 58-59
exact bonds :
17-18 24-25 25-26 25-27 29-30 30-31 31-32 31-33 35-36 42-43 42-44 45-58

normalized bonds :
```



```
1-2 1-6 2-3 3-4 4-5 5-6 36-37 36-41 37-38 38-39 39-40 40-41 45-46 45-
50
46-47 47-48 48-49 49-50 52-53 52-54 53-57 54-55 55-56 56-57


G1:Ak,[*1]

G2:[*2],[*3],[*4],[*5],[*6]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:Atom 15:CLASS 16:CLASS 17:CLASS 18:Atom 19:Atom 20:Atom 21:Atom
22:Atom 23:CLASS
24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS
32:CLASS 33:CLASS
34:CLASS 35:CLASS 36:Atom 37:Atom 38:Atom 39:Atom 40:Atom 41:Atom 42:CLASS
43:CLASS
44:CLASS 45:Atom 46:Atom 47:Atom 48:Atom 49:Atom 50:Atom 51:Atom 52:Atom
53:Atom 54:Atom
55:Atom 56:Atom 57:Atom 58:CLASS 59:CLASS 66:CLASS 67:CLASS
Generic attributes :
12:
Saturation              : Unsaturated
67:
Number of Carbon Atoms : less than 7



L5          86 SEA FILE=REGISTRY SSS FUL L3
L6           4 SEA FILE=CAPLUS ABB=ON  PLU=ON  L5


=> S L6 NOT L11
L15          3 L6 NOT L11

=> D IBIB ED ABS HITSTR L15 1-3

L15 ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         1998:348325  CAPLUS  Full-text
DOCUMENT NUMBER:          129:95463
TITLE:                    Synthesis and biological activities of some new fully
                          fused quinazoline derivatives
AUTHOR(S):                Ibrahim, S. S.; Abdel-Halim, A. M.; Gabr, Y.;
                          El-Edfawy, S.; Abdel-Rahman, R. M.
CORPORATE SOURCE:         Department of Chemistry, Faculty of Education,
                          Ain-Shams University, Cairo, Egypt
SOURCE:                   Indian Journal of Chemistry, Section B: Organic
                          Chemistry Including Medicinal Chemistry (1998),
                          37B(1), 62-67
                          CODEN: IJSBDB; ISSN: 0376-4699
PUBLISHER:                National Institute of Science Communication, CSIR
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
OTHER SOURCE(S):          CASREACT 129:95463
ED   Entered STN:  10 Jun 1998
GI
```




```
AB    Some fused quinazoline derivs. have been synthesized via condensation of 3-
      formylpyrazolo[5,1-b]quinazolin-9(1H)one with bifunctional reagents followed
      by ring closure reactions.  The structures of the products have been
      established by their elemental analyses and spectral data (UV, IR, 1H NMR,
      mass and X-ray).  The antibacterial activity of some products have been also
      described.  I [R = 5-oxo-3-thioxo-hexahydro-1,2,4-triazin-6-yl, CH:CHCOC6H4R1-
      4; R1 = OH, NO2] show a relatively better activity against some tested
      bacteria than gentamycin.
IT    209746-47-4P
      RL: BAC (Biological activity or effector, except adverse); BSU (Biological
      study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL
      (Biological study); PREP (Preparation); RACT (Reactant or reagent)
         (preparation and bactericidal activity of pyrazoloquinazoline derivs.)
RN    209746-47-4  CAPLUS
CN    Pyrazolo[5,1-b]quinazolin-9(4H)-one, 3-[[(2-methyl-4-oxo-3(4H)-
      quinazolinyl)imino]methyl]-  (9CI)  (CA INDEX NAME)
```



```
REFERENCE COUNT:          13    THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 2 OF 3  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         1991:122242  CAPLUS  Full-text
DOCUMENT NUMBER:          114:122242
TITLE:                    Non-steroidal antiinflammatory agents. III: Synthesis
                          of pyrazole derivatives of 4(3H)-quinazolinones
AUTHOR(S):                Farghaly, Ahmed M.; Chaaban, Ibrahim; Khalil, Mounir
                          A.; Bekhit, Adnan A.
CORPORATE SOURCE:         Fac. Pharm., Univ. Alexandria, Alexandria, Egypt
SOURCE:                   Alexandria Journal of Pharmaceutical Sciences (1990),
                          4(1), 52-6
                          CODEN: AJPSES; ISSN: 1110-1792
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
OTHER SOURCE(S):          CASREACT 114:122242
ED   Entered STN:  06 Apr 1991
GI
```



I II III

AB Several groups of compds. were synthesized having a pyrazole or pyrazoline moiety attached to 4(3H)-quinazolinone at the 2- or 3-position either directly or through different linkages. The linkages include methinamino, ethenyl, iminomethyl, aminomethyl or methinehydrazino grouping. Thus, acetanthranil (I) was treated with aminoantipyrine II to give 4(3H)-quinazolinone III. The antiinflammatory activity of representative examples of the products is reported.

IT 132088-33-6P 132088-38-1P 132088-39-2P
132088-40-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 132088-33-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[[3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl]methylene]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 132088-38-1 CAPLUS

CN 4(3H)-Quinazolinone, 2-methyl-3-[[[3-(4-methylphenyl)-1-phenyl-1H-pyrazol-4-yl]methylene]amino]- (9CI) (CA INDEX NAME)



RN 132088-39-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[[3-(4-methylphenyl)-1-phenyl-1H-pyrazol-4-

yl]methylene]amino]-2-phenyl- (9CI) (CA INDEX NAME)



RN 132088-40-5 CAPLUS

CN 4(3H)-Quinazolinone, 3-[[[3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl]methylene]amino]-2-phenyl- (9CI) (CA INDEX NAME)



L15 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1970:43550 CAPLUS Full-text
DOCUMENT NUMBER: 72:43550
TITLE: Triazolylbenzoic acids and acylaminoquinazolones from benzoxazinones and carboxylic acid hydrazides
AUTHOR(S): Ried, Walter; Peters, Bert
CORPORATE SOURCE: Org.-Chem. Inst., Univ. Frankfurt, Frankfurt/M., Fed. Rep. Ger.
SOURCE: Justus Liebigs Annalen der Chemie (1969), 729, 124-38
CODEN: JLACBF; ISSN: 0075-4617
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 72:43550
ED Entered STN: 12 May 1984
GI For diagram(s), see printed CA Issue.
AB 3-(R-Substituted)-5-(R1-substituted)-4-(2-carboxyphenyl)-4H-1,2,4-triazoles (I) (R = H, Me or Ph; R1 = Me, CH2CN, CH2NO2, CH2 oPh, CH2NEt2 or Ph) were prepared from 2-(R-substituted)-4H-3,1-benzoxazines and H2NNHCOR1 in boiling EtOH. In hot C6H6, the reaction yielded 2-(R-substituted)-3- (R1OCNH-substituted)-4(3H)-quinazolinone. Both reactions proceeded via 2-R1OCNHNHC:RNHC6H4CO2-. 3-Methyl-5-cyanomethyl-4-(2-methylphenyl)-4H- 1,2,4-triazole was prepared from 2-MeC6H4N:CMeCl and H2NNHCOCH2CN. I (R = Me, R1 = CH2CN) boiled in Ac2O gave 5-hydroxy-1-methyl-4- cyano-s-triazolo[4,3-a]quinoline (II).
IT 25380-19-2P
RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)

RN 25380-19-2 CAPLUS

CN Pyrazolo[1,5-c]quinazoline-1-carboxamide, 2,3-dihydro-5-methyl-N-(2-methyl-4-oxo-3(4H)-quinazolinyl)- (8CI) (CA INDEX NAME)



=> FILE MARPAT
FILE 'MARPAT' ENTERED AT 10:30:59 ON 25 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

FILE CONTENT: 1961-PRESENT VOL 146 ISS 20 (20070518/ED)

SOME MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 2007078267 05 APR 2007
DE 102005047308 05 APR 2007
EP 1768210 28 MAR 2007
JP 2007082900 05 APR 2007
WO 2007041089 12 APR 2007
GB 2430365 28 MAR 2007
FR 2891276 30 MAR 2007
RU 2296767 10 APR 2007
CA 2556850 24 FEB 2007

Expanded G-group definition display now available.

=> D QUE L14
L3 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L14 1 SEA FILE=MARPAT SSS FUL L3

=> D IBIB AB QHIT 1 L14

L14 ANSWER 1 OF 1 MARPAT COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 140:339338 MARPAT Full-text
TITLE: Preparation of quinazolin-4-one derivatives as PGD2 synthetase inhibitors
INVENTOR(S): Itai, Akiko; Muto, Susumu; Inoue, Tsuyoshi; Urade, Yoshihiro
PATENT ASSIGNEE(S): Institute of Medicinal Molecular Design. Inc., Japan
SOURCE: PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004031180	A1	20040415	WO 2003-JP12648	20031002

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR,

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2503674	A1	20040415	CA 2003-2503674	20031002	
AU 2003268735	A1	20040423	AU 2003-268735	20031002	
GB 2410025	A	20050720	GB 2005-7660	20031002	
GB 2410025	B	20070328			
US 2006229324	A1	20061012	US 2005-529946	20051004	
PRIORITY APPLN. INFO.:			JP 2002-291114	20021003	
			WO 2003-JP12648	20031002	

instant

AB The title compds. I [wherein X = (un)substituted N=CH or NHCH2; R1-R4 = independently H, halo, (un)substituted alkyl, or OH; R = (un)substituted NH2] or pharmaceutically acceptable salts, hydrates, or solvates thereof are prepared as prostaglandin D2 synthase (PGD2) inhibitors. For example, the compound II was prepared in a four-step synthesis. Compds. I showed strong inhibitory effect against human PGD2.

MSTR 1



G1 = alkyl <containing 1-6 C> (opt. substd.)
G5 = 36

Patent location: claim 1
Note: or pharmacologically acceptable salts, hydrates or solvates

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


```
=> D HIS NOFILE

     (FILE 'HOME' ENTERED AT 09:45:09 ON 25 MAY 2007)

     FILE 'CAPLUS' ENTERED AT 09:45:32 ON 25 MAY 2007
                E US2005-529946/APPS
L1             1 SEA ABB=ON  PLU=ON  US2005-529946/APPS
                D SCAN
                SEL RN

     FILE 'REGISTRY' ENTERED AT 09:46:06 ON 25 MAY 2007
L2           142 SEA ABB=ON  PLU=ON  (100-07-2/BI OR 100-63-0/BI OR 101498-88-6/
                 BI OR 1022-46-4/BI OR 105-36-2/BI OR 1073-69-4/BI OR 112351-69-
                 6/BI OR 118-92-3/BI OR 120107-46-2/BI OR 1210-39-5/BI OR
                 126592-16-3/BI OR 126592-17-4/BI OR 13024-90-3/BI OR 132871-77-
                 3/BI OR 134-20-3/BI OR 134017-42-8/BI OR 136304-94-4/BI OR
                 13831-31-7/BI OR 138825-96-4/BI OR 141-97-9/BI OR 14212-87-4/BI
                  OR 14580-22-4/BI OR 14763-20-3/BI OR 147778-06-1/BI OR
                 1710-98-1/BI OR 1711-05-3/BI OR 17364-41-9/BI OR 181185-07-9/BI
                  OR 18600-55-0/BI OR 1898-06-2/BI OR 1904-60-5/BI OR 19386-06-2
                 /BI OR 20676-54-4/BI OR 26759-46-6/BI OR 27006-77-5/BI OR
                 2719-08-6/BI OR 2749-59-9/BI OR 321-07-3/BI OR 3257-39-4/BI OR
                 3282-30-2/BI OR 3471-32-7/BI OR 371120-60-4/BI OR 38163-38-1/BI
                  OR 384353-13-3/BI OR 384812-90-2/BI OR 388109-22-6/BI OR
                 40420-22-2/BI OR 4181-05-9/BI OR 4389-45-1/BI OR 4389-50-8/BI
                 OR 488100-78-3/BI OR 4949-44-4/BI OR 52173-03-2/BI OR 53904-04-
                 4/BI OR 55390-99-3/BI OR 57135-06-5/BI OR 5900-58-3/BI OR
                 60288-17-7/BI OR 60288-19-9/BI OR 60798-06-3/BI OR 63190-57-8/B
                 I OR 638-29-9/BI OR 6402-09-1/BI OR 658703-33-4/BI OR 66299-68-
                 1/BI OR 67836-50-4/BI OR 679843-29-9/BI OR 679843-30-2/BI OR
                 679843-31-3/BI OR 679843-32-4/BI OR 679843-33-5/BI OR 679843-34
                 -6/BI OR 679843-35-7/BI OR 679843-36-8/BI OR 679843-37-9/BI OR
                 679843-38-0/BI OR 679843-39-1/BI OR 679843-40-4/BI OR 679843-41
                 -5/BI OR 679843-42-6/BI OR 679843-43-7/BI OR 679843-44-8/BI OR
                 679843-45-9/BI OR 679843-46-0/BI OR 679843-47-1/BI OR 679843-48
                 -2/BI OR 679843-49-3/BI OR 679843-50-6/BI OR 679843-51-7/BI OR
                 679843-52-8/BI OR 679843-53-9/BI OR 679843-54-0/BI OR 679843-55
                 -1/BI OR 679843-56-2/BI OR 679843-57-3/BI OR 679843-58-4/BI OR
                 679843-59-5/BI OR 679843-60-8/BI OR 679843-61-9/BI OR 679843-62
                 -0/BI OR 679843-63-1/BI OR 679843-64-2/BI OR 679843-65-3/BI OR
                 679843-66-4/BI
L3             STRUCTURE UPLOADED
L4             4 SEA SSS SAM L3
L5            86 SEA SSS FUL L3

     FILE 'CAPLUS' ENTERED AT 10:25:07 ON 25 MAY 2007
L6             4 SEA ABB=ON  PLU=ON  L5
L7           266 SEA ABB=ON  PLU=ON  ITAI A?/AU
L8          1390 SEA ABB=ON  PLU=ON  MUTO S?/AU
L9         11982 SEA ABB=ON  PLU=ON  INOUE T?/AU
L10          262 SEA ABB=ON  PLU=ON  URADE Y?/AU
L11            1 SEA ABB=ON  PLU=ON  (L7 OR L8 OR L9 OR L10) AND L6
L12            1 SEA ABB=ON  PLU=ON  L6 AND P/DT
     FILE 'MARPAT' ENTERED AT 10:27:30 ON 25 MAY 2007
L13            0 SEA SSS SAM L3
L14            1 SEA SSS FUL L3

     FILE 'CAPLUS' ENTERED AT 10:29:16 ON 25 MAY 2007
```



```
L15            3 SEA ABB=ON  PLU=ON  L6 NOT L11
=>
```